Use of diabetes medications in adults with T2D and CVD in Japan: secondary analysis of the CAPTURE study

Yukiko Onishi; Shinichiro Shirabe; Kosei Eguchi; Keiji Nishijima; Toshihiro Sato; Hiroaki Seino

doi:10.1007/s13340-023-00638-w

Use of diabetes medications in adults with T2D and CVD in Japan: secondary analysis of the CAPTURE study

Diabetol Int. 2023 Jun 15;14(4):363-371. doi: 10.1007/s13340-023-00638-w. eCollection 2023 Oct.

Authors

Yukiko Onishi¹, Shinichiro Shirabe², Kosei Eguchi³, Keiji Nishijima³, Toshihiro Sato³, Hiroaki Seino⁴

Affiliations

¹ The Institute of Medical Science, Asahi Life Foundation, 2-2-6 Nihonbashibakurocho, Chuo-ku, Tokyo, 103-0002 Japan.
² HEC Science Clinic, Yokohama, Japan.
³ Novo Nordisk Pharma Ltd., Tokyo, Japan.
⁴ Seino Internal Medicine Clinic, Fukushima, Japan.

Abstract

Introduction: The CAPTURE study estimated the global prevalence of established cardiovascular disease (CVD) and characterized the usage of glucose-lowering agents (GLAs) in adults with type 2 diabetes (T2D) across 13 countries. The purpose of this secondary analysis of data from the Japanese sites within CAPTURE (NCT03786406, NCT03811288) was to provide data about medication usage stratified by CVD status among Japanese participants with T2D.

Materials and methods: Data on GLA usage (including those with proven cardiovascular [CV] benefits) in Japanese participants with T2D managed in clinics or hospitals were collected and stratified by CVD subgroups.

Results: There were 800 Japanese participants in the CAPTURE study (n = 502 [no CVD group], n = 298 [CVD group], n = 268 [atherosclerotic CVD subgroup]). Oral antidiabetic agents and insulin were used by 88.5% and 23.4%, respectively, of participants overall. Among participants with established CVD, dipeptidyl peptidase-4 inhibitors (65.1%) were most frequently used, followed by biguanides (50.7%) and insulins (26.2%). The pattern was similar among participants with atherosclerotic CVD. A lower proportion of participants in the CVD group used glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT-2is) with proven CV benefits versus the no CVD group (GLP-1 RAs: 7.0% vs. 8.6%; SGLT-2is: 13.4% vs. 19.1%).

Conclusion: This analysis of the CAPTURE study provided a comprehensive overview of prescription patterns for the treatment of T2D in Japan. Use of GLAs with proven CV benefit was low, even in participants with established CVD, which was comparable to the findings from the global cohort.

Supplementary information: The online version contains supplementary material available at 10.1007/s13340-023-00638-w.

Keywords: Diabetes mellitus, type 2; Glucagon-like peptide-1; Sodium-glucose cotransporter-2 inhibitors.

© The Japan Diabetes Society 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.